Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET

Company Participants

Ed Berg - Senior Vice President and General Counsel
Steven Lo - Chief Executive Officer
Sean Tucker - Founder and Chief Scientific Officer
James Cummings - Chief Medical Officer
Phil Lee - Chief Financial Officer

Conference Call Participants

Madison Britt Wynne El-Saadi - B. Riley Securities
Aseah Khan - Cantor Fitzgerald
Liang Cheng - Jefferies

Operator

Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to ir@vaxart.com. As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel.

Ed Berg

Good afternoon, and welcome to today's call. Joining us from Vaxart are Steven Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James Cummings, Chief Medical Officer; and Phillip Lee, Chief Financial Officer.

Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10-K and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call.

I'll now turn the call over to Steven Lo. Steve?

Steven Lo

Thanks, Ed, and thanks to all of you for joining us today. On today's call, I'll provide a brief summary of my background, discuss our recent accomplishments and share details of our exciting value proposition. I'll then turn the call over to James and Phil to review our recent progress, which includes positive data from our bivalent norovirus vaccine candidate in lactating mothers, upcoming milestones, and a financial update.

Since this is my first quarterly results call as Vaxart's CEO, I'd like to begin with a brief introduction. I've spent most of my 25-plus-year-career in the healthcare, biotech, and pharmaceutical sectors, including more than 12 years as a C-level executive at publicly-traded biotech companies. Throughout that time, I have led companies through all phases of drug development, from preclinical to launching and commercializing products.